Chemoradiation followed by adjuvant durvalumab in stage III non-small cell lung cancer: Real-world comparison of treatment outcomes to historical controls treated with chemoradiation alone.
Akram SaadJeffrey GoldsteinSarit AppelSameh DaherDamien UrbanAmir OnnHadas Gantz-SorotskyAnastasiya LobachovTeodor GottfriedBenjamin SpielerJair BarPublished in: Thoracic cancer (2022)
Treatment with adjuvant durvalumab following chemoradiation was associated with improved PFS and OS compared to chemoradiation alone.